Connect with us

Biotech

Another biotech gem from Switzerland secures growth capital

Immunos Therapeutics, from the Universities of Zurich and Basel, has received new funds from a financing round. On top of that Daniel Vasella, former CEO of Novartis, has joined the Board of Directors. The new funds are planned to be used during the Phase I clinical trial of the product . Immunos focuses on cancer therapies that target the innate immune system or innate immune defense.

Published

on

This picture show a person using a laptop.

The biotech company Immunos Therapeutics from Schlieren, Germany, which is researching a next-generation cancer drug, has secured $15.27 million (CHF15 million) in a financing round. At first glance, that may appear to be a modest amount in the international health care environment, but the circumstances surrounding the financing are very interesting.

Born2Invest is a digital media website covering the biotech industry, among others. Our companion app allows you to get your daily dose of financial news from industries like banking, cannabis, innovation in biotechnology.

The financing vehicle of a potential strategic partner

One particular aspect of the fundraising process is that Pfizer Ventures, the financing vehicle of a potential strategic partner, is already participating in this first stage of venture financing (Series A Financing). In addition to Pfizer, the Swiss venture capital firm Biomed Partners acts as co-leader of the financing. Other investors include Redalpine, Schroder Adveq, Wille Finance, and Bernina Bioinvest.

“We at Biomed Partners have successfully invested in several early cancer companies over the past seventeen years, including Glycart Biotechnology from Schlieremer, Germany,” said Markus Hosang of Biomed. Immunos and its new approach have particularly appealed to the company, as the treatment has the potential to help patients, alone or in combination with existing cancer drugs, that do not benefit from long-term current therapies.

Daniel Vasella as independent consultant

Markus Hosang of Biomed Partners and Michael Baran of Pfizer joined the Board of Directors of Immunos. Reinhard Ambros, former Managing Director of the Novartis Venture Fund, and Daniel Vasella, former CEO and Chairman of the Board of Directors of Novartis, will join as independent industry consultants.

SEE ALSO  Stock prediction: Step aside, Mr. Bear, the bull continues

In mid-October, Vasella announced his appointment to the board of directors of Numab, a biotech company based in Wädenswil, Germany. The former pharmaceutical manager appears to be ending the “dormancy period” following his commitment to Novartis.

Immunos is a spin-off of the Universities of Zurich and Basel. The company focuses on cancer therapies that target the innate immune system, the nonspecific or innate immune defense. The latest approved cancer therapies are aimed at checkpoint inhibitors that are designed to restart the immobilized immune system. The new funds will be used to finance the Phase I clinical trial of the application.

The novel drug is to be used in the future both as a combined application with checkpoint inhibitors and alone.

The biotech cluster prospers

This financing round brings the up-and-coming biotech cluster Schlieren back into focus. The Bio-Technopark is home to 45 biotech, MedTech and diagnostics companies. The best-known Schlieremer companies include Glycart, which was acquired by Roche in 2005 for $239.38 million (CHF235 million), Molecular Partners, which has been listed on the SIX since 2014, and Kuros, which was created in 2015 through a reverse merger with Cytos Biotechnology.

__

(Featured image by Austin Distel via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Neue Burcher Zeitung, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Sharon Harris is a feminist and a part-time nomad. She reports about businesses primarily involved in tech, CBD, and crypto. She started her career as a product manager at a Silicon Valley startup but now enjoys a new life as a personal finance geek and writer. Her primary aim is to provide readers with a new perspective on the overlapping world of finance and technology.